(Q46862522)

25 December 2017

title

Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

J M Ruiz-Moreno

1

1 reference

25 December 2017

F Gomez-Ulla

2

1 reference

25 December 2017

J A Montero

3

1 reference

25 December 2017

S Ares

4

1 reference

25 December 2017

F Lopez-Lopez

5

1 reference

25 December 2017

M Rodriguez

6

1 reference

25 December 2017

M Fernandez

7

1 reference

25 December 2017

publication date

7 December 2007

1 reference

25 December 2017

published in

Eye

1 reference

25 December 2017

volume

23

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

334-338

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.eye.6703052

exact match

0 references

cites work

Etiology of choroidal neovascularization in young patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Foveal translocation surgery and myopic subfoveal CNV membrane

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Subretinal surgery for choroidal neovascularization in patients with high myopia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Myopic choroidal neovascularization: a 10-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Concentric retinal pigment epithelium atrophy after a single photodynamic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Bevacizumab for neovascular ocular diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6703052

7 January 2021

Identifiers

DOI

10.1038/SJ.EYE.6703052

1 reference

25 December 2017

1 reference

25 December 2017